Medigene offers neoantigen-specific TCRs Until mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the … more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔